The KBI-110 Protocol
– Early data suggest that KBI‑110 synergizes with BCL‑2 inhibitors in AML and with anti‑fibrotic antibodies (e.g., anti‑CTGF) in IPF. A basket trial design could explore these rational combos.
The KBI-110 Protocol
– Early data suggest that KBI‑110 synergizes with BCL‑2 inhibitors in AML and with anti‑fibrotic antibodies (e.g., anti‑CTGF) in IPF. A basket trial design could explore these rational combos.